Robert E. Landry - Dec 8, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Dec 8, 2022
Transactions value $
-$962,523
Form type
4
Date filed
12/12/2022, 03:34 PM
Previous filing
Dec 2, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $1.15M +3K +10.44% $381.92 31.7K Dec 8, 2022 Direct F1
transaction REGN Common Stock Tax liability -$1.74M -2.26K -7.12% $768.54 29.5K Dec 8, 2022 Direct F1
transaction REGN Common Stock Tax liability -$371K -492 -1.67% $753.28 29K Dec 9, 2022 Direct
holding REGN Common Stock 250 Dec 8, 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -3K -44.12% $0.00 3.8K Dec 8, 2022 Common Stock 3K $381.92 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.